TRIAMCINOLONE ACETONIDE 5 mg/g Cream, 15 g
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- Yes, intra-articular triamcinolone is specifically approved to give short-term relief for knee arthritis, gout flares, bursitis, and similar joint conditions. The extended-release...
- I'm getting a triamcinolone injection in my knee. Will it actually help, and how long does it last?
- That's a really important thing to flag with your doctor before your injection or prescription. Triamcinolone can raise blood sugar — even in people whose diabetes is well-controll...
- I have diabetes. Should I be worried about using triamcinolone?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Triamcinolone Acetonide — tap one for details:
Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 5ZA2S6B08X
Cetyl palmitate is a waxy substance made from natural fats. It works as a binder and thickener to help hold the medicine together and control how it dissolves in your body.
-
UNII T5L8T28FGP
Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
-
UNII 1VPU26JZZ4
Potassium sorbate is a salt derived from sorbic acid, a naturally occurring preservative. It prevents growth of mold, yeast, and some bacteria, extending the medicine's shelf life.
-
UNII 6DC9Q167V3
Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
-
UNII X045WJ989B
Sorbic acid is a preservative derived from berries that prevents mold, yeast, and bacterial growth in medicines. It keeps the product stable and safe during storage.
-
UNII 506T60A25R
Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
7 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.190 | $2.85 / 15 g |
| Medicaid paysCMS SDUD · 12 mo | $0.4480 | $6.72 / 15 g |
| Medicare drug plans payPart D · Q2 2026 | $0.1230 | $1.85 / 15 g |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| triamcinolone acetonide 5 mg/g 00168-0002-15 | E. | 1 tube | $0.190 | AT | Availability likely | — |
| Triamcinolone Acetonide 5 mg/g 16714-0987-01 | NorthStar | 1 tube | $0.190 | AT | Availability likely | — |
| Triamcinolone Acetonide 5 mg/g 33342-0328-15 | Macleods | 1 tube | $0.190 | AT | Availability likely | — |
| Triamcinolone Acetonide 5 mg/g 45802-0065-35 | Padagis | 1 tube | $0.190 | AT | Availability likely | — |
| Triamcinolone Acetonide 5 mg/gthis 67877-0318-15 | Ascend | 15 g | $0.190 | AT | Availability likely | — |
| Triamcinolone acetonide 5 mg/g 33342-0332-15 | Macleods | 1 tube | $0.275 | AT | Availability likely | +45% |
| Triamcinolone Acetonide 5 mg/g 45802-0049-35 | Padagis | 1 tube | $0.275 | AT | Availability likely | +45% |
| Triamcinolone acetonide 5 mg/g 16714-0268-01 | NorthStar | 1 tube | $0.275 | AT | Availability likely | +45% |
| Triamcinolone Acetonide 5 mg/g 68462-0798-17 | Glenmark | 1 tube | $0.312 | — | FDA listed | +64% |
| Triderm 5 mg/g 00316-0175-15 | Crown | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 50090-2542-00 | A-S | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 50090-6533-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 63629-8707-01 | Bryant | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 63629-8785-01 | Bryant | 15 g | — | AT | FDA listed | — |
| Triamcinolone acetonide 5 mg/g 68071-2294-05 | NuCare | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 68071-3810-05 | NuCare | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 68071-4397-05 | NuCare | 15 g | — | AT | FDA listed | — |
| Triamcinolone acetonide 5 mg/g 68788-8457-01 | Preferred | 15 g | — | AT | FDA listed | — |
| triamcinolone acetonide 5 mg/g 68788-8892-01 | Preferred | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 70518-1094-00 | REMEDYREPACK | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 70518-2938-00 | REMEDYREPACK | 1 tube | — | AT | FDA listed | — |
| Triamcinolone acetonide 5 mg/g 71205-0009-15 | Proficient | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 71335-2714-01 | Bryant | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 72162-1387-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 72162-1836-02 | Bryant | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 76420-0349-15 | Asclemed | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 63187-0495-15 | Proficient | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 71205-0033-15 | Proficient | 1 tube | — | — | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 71205-0038-15 | Proficient | 1 tube | — | — | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 50090-6211-00 | A-S | 1 tube | — | — | FDA listed | — |
| Triamcinolone acetonide 5 mg/g 82804-0019-15 | Proficient | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide 5 mg/g 50090-5980-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone acetonide 5 mg/g 70518-4205-00 | REMEDYREPACK | 1 tube | — | AT | FDA listed | — |
| Triamcinolone acetonide 5 mg/g 70518-4546-00 | REMEDYREPACK | 1 tube | — | AT | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 67877-0318-15 You're viewing this | 15 g in 1 TUBE (67877-318-15) | 2012-04-01 | Active |
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS & USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
⏱️ Dosage and Administration ▾
DOSAGE & ADMINISTRATION Topical corticosteroids are generally applied to the affected area as a thin film two to four times daily for the 0.025% strength and two or three times daily for the 0.1% and 0.5% strength depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
⛔ Contraindications ▾
CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
🤰 Pregnancy ▾
PREGNANCY CATEGORY C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.
Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
🧒 Pediatric Use ▾
PEDIATRIC USE Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
🆘 Overdosage ▾
OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.
There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.
Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses .
( See DOSAGE AND ADMINISTRATION). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees.
Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Triamcinolone Acetonide Cream USP, 0.025% is supplied in: 15 grams tube NDC 67877-317-15 80 grams tube NDC 67877-317-80 454 grams jar NDC 67877-317-45 Triamcinolone Acetonide Cream USP, 0.1% is supplied in: 15 grams tube NDC 67877-251-15 30 grams tube NDC 67877-251-30 80 grams tube NDC 67877-251-80 454 grams jar NDC 67877-251-45 Triamcinolone Acetonide Cream USP, 0.5% is supplied in: 15 grams tube NDC 67877-318-15 Store at 20°–25°C (68°–77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing.
PRINTED IN USA Manufactured for: Ascend Laboratories, LLC, Parsippany, NJ 07054 Manufactured by: Crown Laboratories, Inc., Johnson City, TN 37604 P1810.02 Revised: DEC 2016
📋 Description ▾
DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Triamcinolone acetonide is a member of this class. Chemically triamcinolone acetonide is pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16, 17-[(1-methylethylidene) bis(oxy)]-(11β16α) Its structural formula is: Each gram of Triamcinolone Acetonide Cream USP, 0.025% contains 0.25 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.
Each gram of Triamcinolone Acetonide Cream USP, 0.1% contains 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Each gram of Triamcinolone Acetonide Cream USP, 0.5% contains 5 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.
Structure
💬 Information for Patients ▾
INFORMATION FOR PATIENTS Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only.
Avoid contact with the eyes. 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician 4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.